Central effects of galcanezumab in migraine: a pilot study on Steady State Visual Evoked Potentials and occipital hemodynamic response in migraine patients

Table 1 Demographic and clinical data of migraine patients at the basal visit (T0) and after 3 months of galcanezumab (240 mg initial dose, 120 mg in the 2nd and 3rd month) (T2) therapy. MA: episodic migraine without aura; CM Chronic Migraine; AED antiepileptics-topiramate and/or valproate; AD antidepressants-amitriptyline; BB beta blockers-propranolol or atenolol; CA calcium channel blockers-flunarizine; TB Botulin Toxin. Frequency was computed as average over 3 months of the number of headache days per month (DAYS/30), symptomatic drug taking was evaluated as average over 3 month of the number of days per month with acute therapy (SIM/30). Headache intensity was expressed with a Numerical Rating Scale –NRS- from 0 no pain to 10 maximal tolerable pain. At the bottom, results of Student’s t test between T0 (basal condition) and T2 (after 3 months of GCA treatment) are reported

	GENDER	AGE	DURATION	DIAGNOSIS	DRUGS	T0	DAYS/30	SIM/30	MIDAS	NRS	DAYS/30	SIM/30	MIDAS	NRS
AI	F	29	20	MA	AED, AD, BB	2	13	13	79	10	17	16	113	10
BA	F	48	30	MA	AED, AD, BB,TB	1	12	12	26	7	8	8	12	4
DD	F	38	22	MA	AED,AD,CA	1	9	9	68	10	4	4	34	10
DE	F	47	25	CM	AED,AD,CA,TB	2	17	17	150	9	17	10	70	6
DI	F	48	25	MA	AED,AD,CA,BB	1	13	13	26	7	10	10	13	6
DL	F	47	24	MA	AED,AD	1	8	12	32	10	3	3	10	6
FA	F	57	40	CM	AED,AD,CA,TB	1	20	20	75	7	4	4	12	8
LE	F	42	30	CM	AED,AD,CA,BB,TB	1	27	27	30	8	6	6	10	6
MA	F	67	50	CM	AED,AD,CA,BB,TB	2	15	4	50	8	15	3	25	5
MO	F	47	30	CM	AED,AD,TB	1	25	25	56	8	12	10	25	7
MN	F	63	45	MA	AED,AD,CA,BB	1	10	12	5	6	5	0	0	4
PN	F	58	10	MA	AED,BB,AD	1	13	13	77	7	8	8	33	7
SM	M	56	30	CM	AED,BB,AD	1	15	15	108	10	5	5	50	8
Mean (SD)							15.5 (8.7)	14.7 (6.2)	60.1 (39.2)	8.2 (1.4)	8.7 (5)	6.6 (4.2)	31.3 (31)	6.6 (2)
T test							3.3	4.3	3.59	3.68
p							0.006	0.001	0.004	0.003

ISSN: 1129-2377